Q32 Bio
QTTB
54 hedge funds and large institutions have $144M invested in Q32 Bio in 2024 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 16 increasing their positions, 6 reducing their positions, and 5 closing their positions.
300% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 5
167% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 6
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
38% more funds holding
Funds holding: 39 → 54 (+15)
15% more capital invested
Capital invested by funds: $126M → $144M (+$18.3M)
162.49% less ownership
Funds ownership: 230.04% → 67.55% (-162%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$7.12M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$4.21M |
| 3 |
HMC
Harvard Management Company
Boston,
Massachusetts
|
+$3.9M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.15M |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
+$2.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$8.36M |
| 2 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$743K |
| 3 |
EAM
Exome Asset Management
New York
|
-$506K |
| 4 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
-$491K |
| 5 |
BCM
BML Capital Management
Zionsville,
Indiana
|
-$424K |
QTTB Hedge Fund Activity: Q2 2024 in Review
54 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Q32 Bio (QTTB) for Q2 2024, worth a combined $144M — up 15% from $126M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new QTTB positions and 5 closed out — a net gain of 15 holders — while 16 added to existing stakes and 6 trimmed.
The largest buyer was BlackRock, adding an estimated $7.12M. The largest seller was Vivo Capital, cutting an estimated $8.36M.
- 54 institutional investors held Q32 Bio (QTTB) as of Q2 2024, up from 39 in Q1 2024.
- Funds reported $144M of Q32 Bio stock for Q2 2024, up 15% quarter-over-quarter.
- 20 funds opened new Q32 Bio positions in Q2 2024 and 5 closed out, a net change of +15 holders.
- The largest Q32 Bio buyer in Q2 2024 was BlackRock, an estimated $7.12M added.
- The largest Q32 Bio seller in Q2 2024 was Vivo Capital, an estimated $8.36M sold.
Based on aggregated 13F filings for Q2 2024.